LUND, Sweden, Oct. 30, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it will attend Truist Securities BioPharma Symposium on November 7 in New York, NY. Hitto Kaufmann, Chief R&D Officer at the Company will participate in a panel discussion entitled, 'Inflammatory Insights: Advancing Novel Therapeutics Across Autoimmune and Inflammatory Indications' on Thursday November 7th from 10:30 to 11:20 AM EST.

Recently Hansa conducted a 12-month follow up analysis of data from the NICE-01 trial of HNSA-5487, the company's next generation molecule. The analysis demonstrates that HNSA-5487 can robustly and very rapidly reduce IgG levels, has redosing potential, and a favorable safety and tolerability profile.

Hansa management will be available for meetings at the conference. If you are interested in meeting with the management team, please contact Hansa Biopharma at ir@hansabiopharma.com.

To learn more about Hansa Biopharma see the latest Corporate Presentation here. The latest investor presentation can be viewed here.

Contacts for more information:
Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com
Stephanie Kenney, VP Global Corporate Affairs
media@hansabiopharma.com

About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa Biopharma has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa Biopharma has a rich and expanding research and development program based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.

^©2024 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma-to-attend-truist-securities-biopharma-symposium,c4057639

The following files are available for download:


     
     https://mb.cision.com/Main/1219/4057639/3079341.pdf 20241017_Truist HC Conf_press
                                                             release_FINAL

View original content:https://www.prnewswire.co.uk/news-releases/hansa-biopharma-to-attend-truist-securities-biopharma-symposium-302291276.html

Tags

More Like This

Hansa Biopharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Hansa Biopharma to host Q2 2024 interim results conference call

Hansa Biopharma Interim Report January-September 2023

Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting

Hansa Biopharma plans restructuring to strengthen long-term competitiveness and advance key deliverables

Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business Update

Hansa Biopharma interim report January-March 2024

Hansa Biopharma: increase in number of shares and votes